BioSpace News Archive

Citius Pharmaceuticals, Inc. today announced that it is set to be added to the broad-market Russell 3000 ® Index and the small-cap Russell 2000 ® Index at the conclusion of the annual reconstitution of Russell US Indexes, effective at the opening of the U.S. equity markets on June 26, 2023.

DarioHealth Corp. (Nasdaq: DRIO) (“Dario” or the “Company”), a leader in the global digital health market, announced today the presentation of research at the American Diabetes Association 83rd Scientific Sessions (the “Scientific Sessions”) demonstrating significant reductions in HbA1c for Dario users compared to non-users.

NorthStar Medical Radioisotopes, LLC and Clarity Pharmaceuticals are pleased to announce the achievement of key milestones in the Cu-67 therapeutic radioisotope production program.

Fractyl Health, an organ-editing metabolic therapeutics company pioneering novel treatments for type 2 diabetes, unveiled compelling 48-week results from the open-label phase of the ongoing Revitalize 1 pivotal study at the American Diabetes Association’s 83rd Scientific Sessions.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced the publication of positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor® in newborn infants, published in the journal Pediatric Drugs.

Therapeutic Solutions International (TSOI) announced today filing with the FDA for Orphan Drug Designation for its JadiCell Adult Stem Cell Product for treatment of Acute Respiratory Distress Syndrome (ARDS).

Genesys Spine today announced the launch of the SIros O™ Oblique SI Fusion system.

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering cell therapies targeting oncology and other diseases, today announced it has completed a Pre-Investigational New Drug (“Pre-IND”) meeting with the FDA.

Makana™ Therapeutics announced that it has been awarded an Artificial Kidney Phase II Prize from KidneyX to continue development of its genetically engineered donor pigs for use in kidney transplantation.

Broadening its commitment to sustainability and corporate social value, Valent BioSciences LLC formally dedicated a new prairie park and solar field adjacent to its manufacturing facility in Osage, Iowa, on June 24.